Hendrik Luesch

Hendrik Luesch, Ph.D.

Professor And Chair, Debbie And Sylvia DeSantis Chair In Natural Products Drug Discovery And Development

Department: Medicinal Chemistry
Business Phone: (352) 273-7738
Business Email: luesch@ufl.edu

About Hendrik Luesch

Hendrik Luesch, Ph.D., a professor of medicinal chemistry, received his Diplom in Chemistry at the University of Siegen (Germany) in 1997. He studied marine natural products chemistry at the University of Hawaii at Manoa and obtained his Ph.D. with Professor Richard E. Moore in 2002. He undertook three years of postdoctoral studies as an Irving S. Sigal Fellow at The Scripps Research Institute with Professor Peter G. Schultz in functional genomics and chemical biology. In 2005 he joined the faculty of the Department of Medicinal Chemistry at the University of Florida (UF) as an assistant professor and was tenured and promoted to associate professor in 2010 and to full professor in 2015. He holds the endowed Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development and serves as Department Chair. He leads a multidisciplinary marine natural products program with chemistry- and genomics-based discovery platforms that integrate classical isolation and spectroscopic structure determination, genome mining and synthetic biology, chemical synthesis, target identification, and mechanism of action as well as early development studies. He is founding Director of UF’s Center for Natural Products, Drug Discovery and Development (CNPD3). He has published over 180 papers, is inventor on 40 issued patents (US, PCT and nationalized) and cofounded several companies. He has received the UF Technology Innovator Award for several years and the UF 2021 Innovation of the Year award.

Related Links:

Teaching Profile

Courses Taught
2009-2024
PHA7980 Research for Doctoral Dissertation
2009-2024
PHA7979 Advanced Research
2010-2012,2015-2020,2020
PHA6971 Research for Master’s Thesis
2006,2015-2018,2018-2021
PHA6935 Selected Topics in Pharmacy
2011-2017,2020-2023,2022-2023
PHA6910 Supervised Research
2011,2013-2015,2015-2019,2017-2023,2019-2024,2021-2024,2023-2024
PHA6356 Structure Determination of Complex Natural Products
2015-2018
PHA5439 Prin Med Chem-Pcol I
2016-2018,2021
PHA5782C Patient Care 2: Introduction to Infectious Disease and Oncology
2018
GMS7980 Research for Doctoral Dissertation
2018
CHM7980 Research for Doctoral Dissertation
2018
CHM7979 Advanced Research
2018
MCB7979 Advanced Research
2014-2018
PHA6905C Research Procedures in Medicinal Chemistry
2012-2016
PHA5438 Medicinal Chemistry 2
2015-2016
GMS6009 Principles of Drug Action and Therapeutics
2011-2015
PHA5437 Medicinal Chemistry 1
2012-2015
PHA6934 Seminar in Medicinal Chemistry
2010,2012-2015,2015
PHA6447 Drug Design
2012-2015
PHA5436 Struc/Func Nucleotide
2009,2011
PHA5906 Research in Med Chem
2024
PHA6467C Drug Design II

Research Profile

Dr. Luesch‘s multidisciplinary research program at the interface of chemistry and biology integrates genome mining, synthetic and chemical biology, isolation and spectroscopic structure determination, chemical synthesis, target identification and mechanism of action studies, followed by the preclinical development of candidate molecules. Under the CNPD3 umbrella, he is leading a collaborative “Genomes to Natural Products to Drugs” initiative. His lab is producing a small but increasing pipeline of bioactive compounds that are at various developmental stages.

His lab has been working closely with chemical ecologist Valerie Paul, Ph.D. (Smithsonian Marine Station) and discovered numerous novel bioactive compounds from marine sources, particularly cyanobacteria, as starting points for drug discovery and development. He discovered the potent microtubule-destabilizer dolastatin 10 from a marine cyanobacterium. Dolastatin 10 has provided the basis for six marketed anticancer drugs to date. Antibody-drug conjugates (ADCs) of the dolastatin 10 analogue MMAE have been FDA approved for Hodgkin’s lymphoma and anaplastic large cell lymphoma (brentuximab vedotin), B-cell lymphoma (polatuzumab vedotin), refractory bladder cancer (enfortumab vedotin), relapsed/refractory multiple myeloma (belantamab mafodotin), various breast, gastric and urothelial cancers (disitamab vedotin), and metastatic cervical cancer (tisotumab vedotin).

His team discovered a new chemical scaffold from marine cyanobacteria, gatorbulin-1, that targets a new tubulin pharmacological site. They reported the entire spectrum of the discovered chemical and biological novelties, including the isolation, structure determination, chemical synthesis, mechanism of action, target identification, and binding mode elucidation at the atomic level. His team discovered, synthesized and performed the in vitro and in vivo evaluation as well as preclinical developmental studies for largazole, one of the most potent class I histone deacetylase (HDAC) inhibitors. He discovered apratoxins and subsequently characterized the novel mechanism of action through genomic and proteomic approaches, revealing that this class of natural products inhibits cotranslational translocation in the secretory pathway. Medicinal chemistry efforts paved the way for the development of synthetic apratoxins for pancreatic and colon cancer, retinal angiogenic diseases, and as broad-spectrum antivirals. His team also discovered, synthesized and tuned selectivity profiles of protease inhibitors, GPCR modulators, cytoskeletal and cell membrane targeting agents, as well as many other natural products with various functions. In general, his team puts significant biology behind all discoveries to enhance the value of the natural products and to enable the best chances for development. He and his team discovered approximately 200 natural products belonging to over 50 chemical scaffolds and have started to identify biosynthetic gene clusters from metagenomes and translating them (or key building blocks) into chemicals to address supply issues through heterologous production or a hybrid synthetic biology/chemistry approach (e.g., apratoxins).

Open Researcher and Contributor ID (ORCID)

0000-0002-4091-7492

Publications

2024
Biosynthesis of Dolastatin 10 in Marine Cyanobacteria, a Prototype for Multiple Approved Cancer Drugs
Organic Letters. 26(7):1321-1325 [DOI] 10.1021/acs.orglett.3c04083. [PMID] 38330916.
2024
Morphological Profiling for Drug Discovery in the Era of Deep Learning.
ArXiv. [PMID] 38168460.
2023
Biosynthesis of Lyngbyastatins 1 and 3, Cytotoxic Depsipeptides from an Okeania sp. Marine Cyanobacterium
Journal of Natural Products. 86(1):85-93 [DOI] 10.1021/acs.jnatprod.2c00782. [PMID] 36546857.
2023
Chlorinated Enyne Fatty Acid Amides from a Marine Cyanobacterium: Discovery of Taveuniamides L-M and Pharmacological Characterization of Taveuniamide F as a GPCR Antagonist with CNR1 Selectivity
Marine Drugs. 22(1) [DOI] 10.3390/md22010028. [PMID] 38248654.
2023
Discovery and Anti-Inflammatory Activity of a Cyanobacterial Fatty Acid Targeting the Keap1/Nrf2 Pathway
Marine Drugs. 21(11) [DOI] 10.3390/md21110553. [PMID] 37999377.
2023
Epigenetic Small-Molecule Screen for Inhibition and Reversal of Acinar Ductal Metaplasia in Mouse Pancreatic Organoids.
bioRxiv : the preprint server for biology. [DOI] 10.1101/2023.11.27.567685. [PMID] 38077007.
2023
Heterologous Production of the C33–C45 Polyketide Fragment of Anticancer Apratoxins in a Cyanobacterial Host
Organic Letters. 25(13):2238-2242 [DOI] 10.1021/acs.orglett.3c00462. [PMID] 36961224.
2023
Isolation and Biological Activity of Iezoside and Iezoside B, SERCA Inhibitors from Floridian Marine Cyanobacteria
Marine Drugs. 21(7) [DOI] 10.3390/md21070378. [PMID] 37504909.
2023
Probing a distinct druggable tubulin binding site with gatorbulins 1–7, their metabolic and physicochemical properties, and pharmacological consequences
Bioorganic & Medicinal Chemistry. 95 [DOI] 10.1016/j.bmc.2023.117506.
2023
Targeted and functional genomics approaches to the mechanism of action of lagunamide D, a mitochondrial cytotoxin from marine cyanobacteria
Biochemical Pharmacology. 213 [DOI] 10.1016/j.bcp.2023.115608. [PMID] 37201874.
2022
An epigenetic small molecule screen to target abnormal nuclear morphology in human cells.
Molecular biology of the cell. 33(6) [DOI] 10.1091/mbc.E21-10-0528. [PMID] 35323046.
2022
Anti-Inflammatory Dysidazirine Carboxylic Acid from the Marine Cyanobacterium Caldora sp. Collected from the Reefs of Fort Lauderdale, Florida
Molecules. 27(5) [DOI] 10.3390/molecules27051717. [PMID] 35268819.
2022
Discovery, Synthesis, and Biological Evaluation of Anaenamides C and D from a New Marine Cyanobacterium, Hormoscilla sp.
Journal of Natural Products. 85(3):581-589 [DOI] 10.1021/acs.jnatprod.1c01073. [PMID] 35167289.
2022
Moringa oleifera Compounds from Seeds and Extracts from Leaves: Anticancer and Cancer Chemopreventive Properties; Preparation of Leaf Extract-based Herbal Syrup.
SciEnggJ. 15:192-227
2022
Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia.
Cell death discovery. 8(1) [DOI] 10.1038/s41420-022-01165-4. [PMID] 36055991.
2022
Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity
ACS Infectious Diseases. 8(7):1265-1279 [DOI] 10.1021/acsinfecdis.2c00008. [PMID] 35766385.
2022
Total Synthesis of des-Thiomethyllooekeyolide A
Organic Letters. 24(40):7260-7264 [DOI] 10.1021/acs.orglett.2c02412. [PMID] 36150127.
2021
A Modular Synthetic Route Involving N-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents
Journal of Medicinal Chemistry. 64(11):7275-7295 [DOI] 10.1021/acs.jmedchem.1c00168. [PMID] 33881312.
2021
Bifunctional Doscadenamides Activate Quorum Sensing in Gram-Negative Bacteria and Synergize with TRAIL to Induce Apoptosis in Cancer Cells
Journal of Natural Products. 84(3):779-789 [DOI] 10.1021/acs.jnatprod.0c01003. [PMID] 33480689.
2021
Function-Oriented and Modular (+/-)-cis-Pseudoguaianolide Synthesis: Discovery of New Nrf2 Activators and NF-κB Inhibitors.
Chemistry (Weinheim an der Bergstrasse, Germany). 27(17):5564-5571 [DOI] 10.1002/chem.202100038. [PMID] 33502811.
2021
Fungal Epithiodiketopiperazines Carrying α,β-Polysulfide Bridges from Penicillium steckii YE, and Their Chemical Interconversion.
Chembiochem : a European journal of chemical biology. 22(2):416-422 [DOI] 10.1002/cbic.202000403. [PMID] 32816319.
2021
Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site
Proceedings of the National Academy of Sciences. 118(9) [DOI] 10.1073/pnas.2021847118. [PMID] 33619102.
2021
Genomic and Targeted Approaches Unveil the Cell Membrane as a Major Target of the Antifungal Cytotoxin Amantelide A
ChemBioChem. 22(10):1790-1799 [DOI] 10.1002/cbic.202000685. [PMID] 33527693.
2021
GPCR Pharmacological Profiling of Aaptamine from the Philippine Sponge Stylissa sp. Extends Its Therapeutic Potential for Noncommunicable Diseases
Molecules. 26(18) [DOI] 10.3390/molecules26185618. [PMID] 34577088.
2021
Heterologous production of cyanobacterial compounds
Journal of Industrial Microbiology and Biotechnology. 48(3-4) [DOI] 10.1093/jimb/kuab003. [PMID] 33928376.
2021
Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm
Current Research in Pharmacology and Drug Discovery. 2 [DOI] 10.1016/j.crphar.2021.100053. [PMID] 34909679.
2021
Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21
Marine Drugs. 19(8) [DOI] 10.3390/md19080471. [PMID] 34436310.
2020
Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis
ACS Medicinal Chemistry Letters. 11(4):419-425 [DOI] 10.1021/acsmedchemlett.9b00473. [PMID] 32292544.
2020
Ahp-Cyclodepsipeptides as tunable inhibitors of human neutrophil elastase and kallikrein 7: Total synthesis of tutuilamide A, serine protease selectivity profile and comparison with lyngbyastatin 7.
Bioorganic & medicinal chemistry. 28(23) [DOI] 10.1016/j.bmc.2020.115756. [PMID] 33002682.
2020
Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFRWTand EGFRT790M
Organic & Biomolecular Chemistry. 18(38):7608-7634 [DOI] 10.1039/d0ob01557a.
2020
Discovery, Total Synthesis, and SAR of Anaenamides A and B: Anticancer Cyanobacterial Depsipeptides with a Chlorinated Pharmacophore
Organic Letters. 22(11):4235-4239 [DOI] 10.1021/acs.orglett.0c01281. [PMID] 32418432.
2020
Dolastatin 15 from a Marine Cyanobacterium Suppresses HIF‐1α Mediated Cancer Cell Viability and Vascularization
ChemBioChem. 21(16):2356-2366 [DOI] 10.1002/cbic.202000180. [PMID] 32237262.
2020
High-throughput gene screen reveals modulators of nuclear shape.
Molecular biology of the cell. 31(13):1392-1402 [DOI] 10.1091/mbc.E19-09-0520. [PMID] 32320319.
2020
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases
ACS Chemical Neuroscience. 11(13):1937-1943 [DOI] 10.1021/acschemneuro.0c00093. [PMID] 32559056.
2020
Natural products as modulators of eukaryotic protein secretion
Natural Product Reports. 37(5):717-736 [DOI] 10.1039/c9np00066f. [PMID] 32067014.
2020
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine’s Biological Activity
Journal of Medicinal Chemistry. 63(10):5119-5138 [DOI] 10.1021/acs.jmedchem.9b01924. [PMID] 31913038.
2020
Seaweed natural products modify the host inflammatory response via Nrf2 signaling and alter colon microbiota composition and gene expression.
Free radical biology & medicine. 146:306-323 [DOI] 10.1016/j.freeradbiomed.2019.09.013. [PMID] 31536771.
2020
Targeting and extending the eukaryotic druggable genome with natural products
Natural Product Reports. 37(6):744-746 [DOI] 10.1039/d0np90021d. [PMID] 32525143.
2020
Targeting eukaryotic proteases for natural products-based drug development
Natural Product Reports. 37(6):827-860 [DOI] 10.1039/c9np00060g. [PMID] 32519686.
2020
Tutuilamides A–C: Vinyl-Chloride-Containing Cyclodepsipeptides from Marine Cyanobacteria with Potent Elastase Inhibitory Properties
ACS Chemical Biology. 15(3):751-757 [DOI] 10.1021/acschembio.9b00992. [PMID] 31935054.
2020
Vicinal difluorination as a C=C surrogate: an analog of piperine with enhanced solubility, photostability, and acetylcholinesterase inhibitory activity.
Beilstein journal of organic chemistry. 16:2663-2670 [DOI] 10.3762/bjoc.16.216. [PMID] 33178356.
2020
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
Bioorganic & medicinal chemistry. 28(14) [DOI] 10.1016/j.bmc.2020.115546. [PMID] 32616180.
2019
Advances in exploring the therapeutic potential of marine natural products.
Pharmacological research. 147 [DOI] 10.1016/j.phrs.2019.104373. [PMID] 31351913.
2019
Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.
Investigative ophthalmology & visual science. 60(8):3254-3263 [DOI] 10.1167/iovs.19-26936. [PMID] 31361305.
2019
Chemical and Metagenomic Studies of the Lethal Black Band Disease of Corals Reveal Two Broadly Distributed, Redox-Sensitive Mixed Polyketide/Peptide Macrocycles
Journal of Natural Products. 82(1):111-121 [DOI] 10.1021/acs.jnatprod.8b00804. [PMID] 30636420.
2019
Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model
Investigational New Drugs. 37(2):364-374 [DOI] 10.1007/s10637-018-0647-0. [PMID] 30073464.
2019
Discovery and Total Synthesis of Doscadenamide A: A Quorum Sensing Signaling Molecule from a Marine Cyanobacterium
Organic Letters. 21(18):7274-7278 [DOI] 10.1021/acs.orglett.9b02525. [PMID] 31414826.
2019
Discovery of Amantamide, a Selective CXCR7 Agonist from Marine Cyanobacteria
Organic Letters. 21(6):1622-1626 [DOI] 10.1021/acs.orglett.9b00163. [PMID] 30779584.
2019
Isolation, Structure Elucidation and Biological Evaluation of Lagunamide D: A New Cytotoxic Macrocyclic Depsipeptide from Marine Cyanobacteria
Marine Drugs. 17(2) [DOI] 10.3390/md17020083. [PMID] 30717076.
2019
New methods for isolation and structure determination of natural products
Natural Product Reports. 36(7):942-943 [DOI] 10.1039/c9np90023c.
2019
Total Synthesis of Endolides A and B.
Synlett : accounts and rapid communications in synthetic organic chemistry. 30(20):2279-2284 [DOI] 10.1055/s-0037-1610736. [PMID] 34163101.
2018
A Complementary Chemical and Genomic Screening Approach for Druggable Targets in the Nrf2 Pathway and Small Molecule Inhibitors to Overcome Cancer Cell Drug Resistance
ACS Chemical Biology. 13(5):1189-1199 [DOI] 10.1021/acschembio.7b01025. [PMID] 29565554.
2018
An Efficient Buchwald–Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration
Journal of Medicinal Chemistry. 61(9):3962-3983 [DOI] 10.1021/acs.jmedchem.7b01903.
2018
Apratyramide, a Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing
ACS Chemical Biology. 13(1):91-99 [DOI] 10.1021/acschembio.7b00827. [PMID] 29205032.
2018
Correction to Apratoxin E, a Cytotoxic Peptolide from a Guamanian Collection of the Marine Cyanobacterium Lyngbya bouillonii
Journal of Natural Products. 81(1):217-217 [DOI] 10.1021/acs.jnatprod.7b00982.
2018
Cover Feature: Structural Diversity and Anticancer Activity of Marine‐Derived Elastase Inhibitors: Key Features and Mechanisms Mediating the Antimetastatic Effects in Invasive Breast Cancer (ChemBioChem 8/2018)
ChemBioChem. 19(8):765-765 [DOI] 10.1002/cbic.201800138.
2018
Discovery of new A- and B-type laxaphycins with synergistic anticancer activity.
Bioorganic & medicinal chemistry. 26(9):2310-2319 [DOI] 10.1016/j.bmc.2018.03.022. [PMID] 29606488.
2018
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A–E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium
Journal of Medicinal Chemistry. 61(14):6364-6378 [DOI] 10.1021/acs.jmedchem.8b00885. [PMID] 30015488.
2018
High-Yield Production of Herbicidal Thaxtomins and Thaxtomin Analogs in a Nonpathogenic Streptomyces Strain.
Applied and environmental microbiology. 84(11) [DOI] 10.1128/AEM.00164-18. [PMID] 29602787.
2018
Isolation and Characterization of Anaephenes A–C, Alkylphenols from a Filamentous Cyanobacterium (Hormoscilla sp., Oscillatoriales)
Journal of Natural Products. 81(12):2716-2721 [DOI] 10.1021/acs.jnatprod.8b00650. [PMID] 30489078.
2018
Photosynthetic Production of Sunscreen Shinorine Using an Engineered Cyanobacterium
ACS Synthetic Biology. 7(2):664-671 [DOI] 10.1021/acssynbio.7b00397.
2018
Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor
Organic Process Research & Development. 22(2):190-199 [DOI] 10.1021/acs.oprd.7b00352. [PMID] 37332527.
2018
Rational engineering of Streptomyces albus J1074 for the overexpression of secondary metabolite gene clusters
Microbial Cell Factories. 17(1) [DOI] 10.1186/s12934-018-0874-2. [PMID] 29454348.
2018
Structural Diversity and Anticancer Activity of Marine‐Derived Elastase Inhibitors: Key Features and Mechanisms Mediating the Antimetastatic Effects in Invasive Breast Cancer
ChemBioChem. 19(8):815-825 [DOI] 10.1002/cbic.201700627. [PMID] 29405541.
2018
The adaptive regulation of thiamine pyrophosphokinase-1 facilitates malignant growth during supplemental thiamine conditions.
Oncotarget. 9(83):35422-35438 [DOI] 10.18632/oncotarget.26259. [PMID] 30459934.
2018
The nucleus is irreversibly shaped by motion of cell boundaries in cancer and non-cancer cells.
Journal of cellular physiology. 233(2):1446-1454 [DOI] 10.1002/jcp.26031. [PMID] 28542912.
2018
Total Synthesis of Asperphenins A and B
Organic Letters. 20(19):6170-6173 [DOI] 10.1021/acs.orglett.8b02652. [PMID] 30232896.
2017
A Highly Potent Class of Halogenated Phenazine Antibacterial and Biofilm-Eradicating Agents Accessed Through a Modular Wohl-Aue Synthesis.
Scientific reports. 7(1) [DOI] 10.1038/s41598-017-01045-3. [PMID] 28515440.
2017
A Tryptoline Ring-Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole Alkaloid Yohimbine.
Chemistry (Weinheim an der Bergstrasse, Germany). 23(18):4327-4335 [DOI] 10.1002/chem.201604795. [PMID] 27900785.
2017
Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors
ACS Medicinal Chemistry Letters. 8(10):1007-1012 [DOI] 10.1021/acsmedchemlett.7b00192. [PMID] 29057042.
2017
Correction to “Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors”
ACS Medicinal Chemistry Letters. 8(12):1342-1342 [DOI] 10.1021/acsmedchemlett.7b00498. [PMID] 29266134.
2017
Cyanobacterial Sfp-type phosphopantetheinyl transferases functionalize carrier proteins of diverse biosynthetic pathways.
Scientific reports. 7(1) [DOI] 10.1038/s41598-017-12244-3. [PMID] 28928426.
2017
Grassystatins D–F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer
Journal of Natural Products. 80(11):2969-2986 [DOI] 10.1021/acs.jnatprod.7b00551. [PMID] 29087712.
2017
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer
Marine Drugs. 15(9) [DOI] 10.3390/md15090290. [PMID] 28926939.
2017
Poly(N-(2-Hydroxypropyl) Methacrylamide)-Valproic Acid Conjugates as Block Copolymer Nanocarriers.
Polymer chemistry. 8(34):4983-4987 [DOI] 10.1039/C7PY00196G. [PMID] 28959359.
2017
Synthesis and biological evaluation of largazole zinc-binding group analogs.
Bioorganic & medicinal chemistry. 25(12):3077-3086 [DOI] 10.1016/j.bmc.2017.03.071. [PMID] 28416100.
2016
Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata.
Journal of natural products. 79(7):1867-71 [DOI] 10.1021/acs.jnatprod.6b00203. [PMID] 27380142.
2016
Correction to Caylobolide B, a Macrolactone from Symplostatin 1-Producing Marine Cyanobacteria Phormidium spp. from Florida.
Journal of natural products. 79(2) [DOI] 10.1021/acs.jnatprod.6b00120. [PMID] 26885760.
2016
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.
Breast cancer research : BCR. 18(1) [DOI] 10.1186/s13058-016-0741-1. [PMID] 27495374.
2016
Discovery, Total Synthesis and Key Structural Elements for the Immunosuppressive Activity of Cocosolide, a Symmetrical Glycosylated Macrolide Dimer from Marine Cyanobacteria.
Chemistry (Weinheim an der Bergstrasse, Germany). 22(24):8158-66 [DOI] 10.1002/chem.201600674. [PMID] 27139508.
2016
Pitiamides A and B, Multifunctional Fatty Acid Amides from Marine Cyanobacteria.
Planta medica. 82(9-10):897-902 [DOI] 10.1055/s-0042-105157. [PMID] 27135625.
2016
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
Journal of medicinal chemistry. 59(8):3808-25 [DOI] 10.1021/acs.jmedchem.5b02004. [PMID] 27018907.
2016
Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium.
Bioorganic & medicinal chemistry. 24(15):3276-82 [DOI] 10.1016/j.bmc.2016.04.062. [PMID] 27211244.
2016
Total Synthesis and Biological Evaluation of Apratoxin E and Its C30 Epimer: Configurational Reassignment of the Natural Product.
Organic letters. 18(20):5400-5403 [DOI] 10.1021/acs.orglett.6b02780. [PMID] 27723359.
2016
Total Synthesis of the Potent Marine-Derived Elastase Inhibitor Lyngbyastatin 7 and in Vitro Biological Evaluation in Model Systems for Pulmonary Diseases.
The Journal of organic chemistry. 81(2):532-44 [DOI] 10.1021/acs.joc.5b02386. [PMID] 26709602.
2015
A dive into membrane dynamics with sponge peptides.
Chemistry & biology. 22(5):565-7 [DOI] 10.1016/j.chembiol.2015.05.003. [PMID] 26000744.
2015
Amantelides A and B, Polyhydroxylated Macrolides with Differential Broad-Spectrum Cytotoxicity from a Guamanian Marine Cyanobacterium.
Journal of natural products. 78(8):1957-62 [DOI] 10.1021/acs.jnatprod.5b00293. [PMID] 26204500.
2015
Biological targets and mechanisms of action of natural products from marine cyanobacteria.
Natural product reports. 32(3):478-503 [DOI] 10.1039/c4np00104d. [PMID] 25571978.
2015
Caldora penicillata gen. nov., comb. nov. (cyanobacteria), a pantropical marine species with biomedical relevance.
Journal of phycology. 51(4):670-81 [PMID] 26327714.
2015
Discovery of ML358, a Selective Small Molecule Inhibitor of the SKN-1 Pathway Involved in Drug Detoxification and Resistance in Nematodes.
ACS chemical biology. 10(8):1871-9 [DOI] 10.1021/acschembio.5b00304. [PMID] 25946346.
2015
Halogenated Phenazines that Potently Eradicate Biofilms, MRSA Persister Cells in Non-Biofilm Cultures, and Mycobacterium tuberculosis.
Angewandte Chemie (International ed. in English). 54(49):14819-23 [DOI] 10.1002/anie.201508155. [PMID] 26480852.
2015
Targeted natural products discovery from marine cyanobacteria using combined phylogenetic and mass spectrometric evaluation.
Journal of natural products. 78(3):486-92 [DOI] 10.1021/np500931q. [PMID] 25635943.
2014
Evaluation of class I HDAC isoform selectivity of largazole analogues.
Bioorganic & medicinal chemistry letters. 24(16):3728-31 [DOI] 10.1016/j.bmcl.2014.07.006. [PMID] 25070421.
2014
Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation.
Chembiochem : a European journal of chemical biology. 15(6):799-804 [DOI] 10.1002/cbic.201300762. [PMID] 24591193.
2014
Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity.
Journal of medicinal chemistry. 57(7):3011-29 [DOI] 10.1021/jm4019965. [PMID] 24660812.
2014
Improved Total Synthesis and Biological Evaluation of Potent Apratoxin S4 Based Anticancer Agents With Enhanced Activity
Planta Medica. 80(10)
2014
Largazole pharmacokinetics in rats by LC-MS/MS.
Marine drugs. 12(3):1623-40 [DOI] 10.3390/md12031623. [PMID] 24658499.
2014
Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
ACS medicinal chemistry letters. 5(8):905-10 [DOI] 10.1021/ml500170r. [PMID] 25147612.
2013
Cultivated sea lettuce is a multiorgan protector from oxidative and inflammatory stress by enhancing the endogenous antioxidant defense system.
Cancer prevention research (Philadelphia, Pa.). 6(9):989-99 [DOI] 10.1158/1940-6207.CAPR-13-0014. [PMID] 24005795.
2013
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Oncogene. 32(10):1316-29 [DOI] 10.1038/onc.2012.138. [PMID] 22543582.
2013
In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway.
ACS chemical biology. 8(8):1764-74 [DOI] 10.1021/cb4000103. [PMID] 23773140.
2013
Modular strategies for structure and function employed by marine cyanobacteria: characterization and synthesis of pitinoic acids.
Organic letters. 15(16):4050-3 [DOI] 10.1021/ol401396u. [PMID] 23915229.
2013
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.
Journal of medicinal chemistry. 56(3):1276-90 [DOI] 10.1021/jm3017305. [PMID] 23350733.
2013
Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2-ARE pathway.
Free radical biology & medicine. 57:141-53 [DOI] 10.1016/j.freeradbiomed.2012.12.019. [PMID] 23291594.
2013
Total synthesis and biological evaluation of grassypeptolide A.
Chemistry (Weinheim an der Bergstrasse, Germany). 19(21):6774-84 [DOI] 10.1002/chem.201203667. [PMID] 23536467.
2012
Chemistry and Biology of Novel Cyanobacterial Secondary Metabolites From Guam
Planta Medica. 78
2012
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
Journal of medicinal chemistry. 55(23):10749-65 [DOI] 10.1021/jm301630s. [PMID] 23181502.
2012
Discovery and mechanism of natural products as modulators of histone acetylation.
Current drug targets. 13(8):1029-47 [PMID] 22594471.
2012
Largazole: from discovery to broad-spectrum therapy.
Natural product reports. 29(4):449-56 [DOI] 10.1039/c2np00066k. [PMID] 22334030.
2012
Marine cyanobacterial fatty acid amides acting on cannabinoid receptors.
Chembiochem : a European journal of chemical biology. 13(18):2676-81 [DOI] 10.1002/cbic.201200502. [PMID] 23143757.
2012
Novel Elastase Inhibitors From Marine Cyanobacteria: Structural Diversity, Target-Bound Crystal Structures and Cellular Effects
Planta Medica. 78
2012
Total synthesis of grassystatin A, a probe for cathepsin E function.
Bioorganic & medicinal chemistry. 20(15):4774-80 [DOI] 10.1016/j.bmc.2012.05.077. [PMID] 22748705.
2011
Bioactive Modified Peptides From Marine Cyanobacteria
Biopolymers. 96
2011
Biological effects of Byrsocarpus coccineus in vitro.
Pharmaceutical biology. 49(2):152-60 [DOI] 10.3109/13880209.2010.504967. [PMID] 21110733.
2011
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
Oncology reviews. 5(3):177-184 [PMID] 21949574.
2011
Combination therapy for renal cell cancer: what are possible options?
Oncology. 81(3-4):220-9 [DOI] 10.1159/000333470. [PMID] 22085914.
2011
Combination therapy targeting cancer metabolism.
Medical hypotheses. 76(2):169-72 [DOI] 10.1016/j.mehy.2010.09.008. [PMID] 20947261.
2011
In Vitro and In Vivo Osteogenic Activity of Largazole.
ACS medicinal chemistry letters. 2(3):248-251 [PMID] 21666868.
2011
Lyngbyoic acid, a “tagged” fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa.
Molecular bioSystems. 7(4):1205-16 [DOI] 10.1039/c0mb00180e. [PMID] 21258753.
2011
Malyngamide 3 and cocosamides A and B from the marine cyanobacterium Lyngbya majuscula from Cocos Lagoon, Guam.
Journal of natural products. 74(4):871-6 [DOI] 10.1021/np1008015. [PMID] 21341718.
2011
Marine natural products: a new wave of drugs?
Future medicinal chemistry. 3(12):1475-89 [DOI] 10.4155/fmc.11.118. [PMID] 21882941.
2011
Pitipeptolides C-F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula from Guam.
Phytochemistry. 72(16):2068-74 [DOI] 10.1016/j.phytochem.2011.07.014. [PMID] 21843895.
2011
Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya majuscula from Guam.
Journal of natural products. 74(1):109-12 [DOI] 10.1021/np1006839. [PMID] 21138309.
2011
Porpoisamides A and B, two novel epimeric cyclic depsipeptides from a Florida Keys collection of Lyngbya sp.
Bioorganic & medicinal chemistry. 19(22):6576-80 [DOI] 10.1016/j.bmc.2011.05.051. [PMID] 21705224.
2011
Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.
ACS medicinal chemistry letters. 2(11):861-865 [PMID] 22081789.
2011
Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. hydnoides from Guam.
Journal of natural products. 74(5):917-27 [DOI] 10.1021/np200076t. [PMID] 21446699.
2010
A small-molecule inducer of the antioxidant response element.
Chemistry & biology. 17(5):537-47 [DOI] 10.1016/j.chembiol.2010.03.013. [PMID] 20534351.
2010
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
The Journal of pharmacology and experimental therapeutics. 335(2):351-61 [DOI] 10.1124/jpet.110.172387. [PMID] 20739454.
2010
Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria Phormidium spp. from Florida.
Journal of natural products. 73(9):1606-9 [DOI] 10.1021/np100467d. [PMID] 20806908.
2010
Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam.
Journal of natural products. 73(9):1544-52 [DOI] 10.1021/np1004032. [PMID] 20704304.
2010
Grassypeptolides A-C, cytotoxic bis-thiazoline containing marine cyclodepsipeptides.
The Journal of organic chemistry. 75(23):8012-23 [DOI] 10.1021/jo1013564. [PMID] 21047144.
2010
Intramolecular modulation of serine protease inhibitor activity in a marine cyanobacterium with antifeedant properties.
Marine drugs. 8(6):1803-16 [DOI] 10.3390/md8061803. [PMID] 20631871.
2010
Isolation and biological evaluation of 8-epi-malyngamide C from the Floridian marine cyanobacterium Lyngbya majuscula.
Journal of natural products. 73(3):463-6 [DOI] 10.1021/np900614n. [PMID] 20166701.
2010
Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis.
Journal of natural products. 73(3):459-62 [DOI] 10.1021/np900603f. [PMID] 20020755.
2010
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression.
Nature cell biology. 12(8):758-67 [DOI] 10.1038/ncb2080. [PMID] 20622870.
2010
Weapons in disguise–activating mechanisms and protecting group chemistry in nature.
Chemistry (Weinheim an der Bergstrasse, Germany). 16(44):13020-9 [DOI] 10.1002/chem.201001562. [PMID] 20931575.
2009
A natural products approach to drug discovery: probing modes of action of antitumor agents by genome-scale cDNA library screening.
Methods in molecular biology (Clifton, N.J.). 572:261-77 [DOI] 10.1007/978-1-60761-244-5_17. [PMID] 20694698.
2009
Activation of the antioxidant response element by specific oxidized metabolites of linoleic acid.
Prostaglandins, leukotrienes, and essential fatty acids. 81(1):53-9 [DOI] 10.1016/j.plefa.2009.04.008. [PMID] 19481916.
2009
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation.
Molecular pharmacology. 76(1):91-104 [DOI] 10.1124/mol.109.056085. [PMID] 19403701.
2009
Bioassay-guided isolation and identification of desacetylmicrocolin B from Lyngbya cf. polychroa.
Planta medica. 75(13):1427-30 [DOI] 10.1055/s-0029-1185675. [PMID] 19431099.
2009
Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Chembiochem : a European journal of chemical biology. 10(10):1634-9 [DOI] 10.1002/cbic.200900192. [PMID] 19514039.
2009
Construction and characterization of melanocortin-2 and -4 receptor chimeras.
Advances in experimental medicine and biology. 611:301-2 [PMID] 19400202.
2009
Construction and Characterization of Melanocortin-2 And-4 Receptor Chimeras
. 611:301-302 [DOI] 10.1007/978-0-387-73657-0\_135.
2009
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.
Journal of medicinal chemistry. 52(18):5732-47 [DOI] 10.1021/jm9009394. [PMID] 19715320.
2009
Largamides A-C, tiglic acid-containing cyclodepsipeptides with elastase-inhibitory activity from the marine cyanobacterium Lyngbya confervoides.
Planta medica. 75(5):528-33 [DOI] 10.1055/s-0029-1185332. [PMID] 19214948.
2009
Lyngbyastatins 8-10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena.
Marine drugs. 7(4):528-38 [DOI] 10.3390/md7040528. [PMID] 20098596.
2009
Novel Natural Activators of the Antioxidant Response Element
Journal of the Neurological Sciences. 285
2009
Phylogenetic and chemical diversity of three chemotypes of bloom-forming lyngbya species (Cyanobacteria: Oscillatoriales) from reefs of southeastern Florida.
Applied and environmental microbiology. 75(9):2879-88 [DOI] 10.1128/AEM.02656-08. [PMID] 19270119.
2009
Protection of human cultured cells against oxidative stress by Rhodiola rosea without activation of antioxidant defenses.
Free radical biology & medicine. 47(5):577-84 [DOI] 10.1016/j.freeradbiomed.2009.05.025. [PMID] 19486939.
2009
Tiglicamides A-C, cyclodepsipeptides from the marine cyanobacterium Lyngbya confervoides.
Phytochemistry. 70(17-18):2058-63 [DOI] 10.1016/j.phytochem.2009.09.010. [PMID] 19815244.
2008
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii.
Journal of natural products. 71(6):1113-6 [DOI] 10.1021/np700717s. [PMID] 18461997.
2008
Bioactive Natural Products From Marine Cyanobacteria: New Structures and Modes of Action
Planta Medica. 74
2008
Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbya polychroa.
Journal of natural products. 71(5):887-90 [DOI] 10.1021/np0706769. [PMID] 18393465.
2008
Genome-wide overexpression screen for activators of antioxidant gene transcription.
Methods in molecular biology (Clifton, N.J.). 477:343-54 [DOI] 10.1007/978-1-60327-517-0_26. [PMID] 19082959.
2008
Kempopeptins A and B, serine protease inhibitors with different selectivity profiles from a marine cyanobacterium, Lyngbya sp.
Journal of natural products. 71(9):1625-9 [DOI] 10.1021/np8002172. [PMID] 18693761.
2008
Orgn 523-Total Synthesis of Largazole
. 236
2008
Pompanopeptins a and B, New Cyclic Peptides From the Marine Cyanobacterium Lyngbya Confervoides
Tetrahedron. 64(18):4081-4089 [DOI] 10.1016/j.tet.2008.02.035.
2008
Serine Protease Inhibitors From the Floridian Marine Cyanobacterium Lyngbya Confervoides
Planta Medica. 74:1037-1038
2008
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp.
Journal of the American Chemical Society. 130(6):1806-7 [DOI] 10.1021/ja7110064. [PMID] 18205365.
2008
Structure and Activity of Largazole, a Potent Antiproliferative Agent From the Floridian Marine Cyanobacterium Symploca Sp.
Journal of the American Chemical Society. 130 [DOI] 10.1021/ja710064S0002-7863(71)01006-0.
2008
Synthesis and activity of largazole analogues with linker and macrocycle modification.
Organic letters. 10(18):4021-4 [DOI] 10.1021/ol801532s. [PMID] 18707106.
2008
Total Structure Determination of Grassypeptolide, a New Marine Cyanobacterial Cytotoxin
Organic Letters. 10:789-792 [DOI] 10.1021/0l702946d.
2008
Total structure determination of grassypeptolide, a new marine cyanobacterial cytotoxin.
Organic letters. 10(5):789-92 [DOI] 10.1021/ol702946d. [PMID] 18220404.
2008
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Journal of the American Chemical Society. 130(26):8455-9 [DOI] 10.1021/ja8013727. [PMID] 18507379.
2007
A genomic screen for activators of the antioxidant response element.
Proceedings of the National Academy of Sciences of the United States of America. 104(12):5205-10 [PMID] 17360324.
2007
Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides.
Journal of natural products. 70(1):124-7 [PMID] 17253864.
2007
Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp.
Journal of natural products. 70(10):1593-600 [PMID] 17910513.
2006
A functional genomics approach to the mode of action of apratoxin A.
Nature chemical biology. 2(3):158-67 [PMID] 16474387.
2006
Towards high-throughput characterization of small molecule mechanisms of action.
Molecular bioSystems. 2(12):609-20 [PMID] 17216042.
2005
A genome-wide overexpression screen in yeast for small-molecule target identification.
Chemistry & biology. 12(1):55-63 [PMID] 15664515.
2003
Biosynthesis of 4-methylproline in cyanobacteria: cloning of nosE and nosF genes and biochemical characterization of the encoded dehydrogenase and reductase activities.
The Journal of organic chemistry. 68(1):83-91 [PMID] 12515465.
2003
Continuing studies on the cyanobacterium Lyngbya sp.: isolation and structure determination of 15-norlyngbyapeptin A and lyngbyabellin D.
Journal of natural products. 66(5):595-8 [PMID] 12762789.
2003
The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
International journal of cancer. 104(4):512-21 [PMID] 12584751.
2002
Lyngbyaloside B, a new glycoside macrolide from a Palauan marine cyanobacterium, Lyngbya sp.
Journal of natural products. 65(12):1945-8 [PMID] 12502348.
2002
New apratoxins of marine cyanobacterial origin from Guam and Palau.
Bioorganic & medicinal chemistry. 10(6):1973-8 [PMID] 11937357.
2002
Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.
Journal of natural products. 65(1):16-20 [PMID] 11809057.
2002
Ulongamides A-F, new beta-amino acid-containing cyclodepsipeptides from Palauan collections of the marine cyanobacterium Lyngbya sp.
Journal of natural products. 65(7):996-1000 [PMID] 12141859.
2001
Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula.
Journal of natural products. 64(3):304-7 [PMID] 11277744.
2000
Apramides A-G, novel lipopeptides from the marine cyanobacterium Lyngbya majuscula.
Journal of natural products. 63(8):1106-12 [PMID] 10978206.
2000
Isolation and structure of the cytotoxin lyngbyabellin B and absolute configuration of lyngbyapeptin A from the marine cyanobacterium Lyngbya majuscula.
Journal of natural products. 63(10):1437-9 [PMID] 11076573.
2000
Isolation, structure determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium lyngbya majuscula.
Journal of natural products. 63(5):611-5 [PMID] 10843570.
1999
Lyngbyastatin 2 and norlyngbyastatin 2, analogues of dolastatin G and nordolastatin G from the marine cyanobacterium Lyngbya majuscula.
Journal of natural products. 62(12):1702-6 [PMID] 10654420.
1999
Symplostatin 2: a dolastatin 13 analogue from the marine cyanobacterium Symploca hydnoides.
Journal of natural products. 62(4):655-8 [PMID] 10217737.
1999
Tumonoic acids, novel metabolites from a cyanobacterial assemblage of Lyngbya majuscula and Schizothrix calcicola.
Journal of natural products. 62(3):464-7 [PMID] 10096859.
1998
Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides.
Journal of natural products. 61(9):1075-7 [PMID] 9748368.

Grants

Oct 2023 ACTIVE
Anti-Cancer Drug Leads from Marine Sponges Collected Off the Coasts of Kalangahan, Lugait, Misamis Oriental
Role: Principal Investigator
Funding: MINDANAO STATE UNIVERSITY via SCIENCE EDUCATION INSTITUTE
Sep 2022 ACTIVE
UF HEALTH CANCER CENTER PILOT PROJECTS GRANTS FUNDED THROUGHTHE FLORIDA CONSORTIUM OF NATIONAL CANCER INSTITUTE CENTER
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Aug 2022 ACTIVE
Integrative Multidisciplinary Discovery Platform to Unlock Marine Natural Products Therapeutic Opportunities
Role: Principal Investigator
Funding: NATL INST OF HLTH NIGMS
Aug 2021 – Aug 2023
Discovery and Mechanistic Characterization of New Cytotoxic Agents from Marine Cyanobacteria
Role: Other
Funding: NATL INST OF HLTH NIGMS
Jun 2020 – Jun 2022
NMR console upgrade for structural biology and metabolomics
Role: Faculty
Funding: NATL INST OF HLTH OD
Sep 2019 ACTIVE
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Aug 2019 – Mar 2020
Potential Anticancer Drug Leads from the Marine Sponges Collected off the Coast of Surigao City
Role: Principal Investigator
Funding: MINDANAO STATE UNIVERSITY via SCIENCE EDUCATION INSTITUTE
Dec 2018 – May 2021
Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B Enhancers
Role: Project Manager
Funding: MAYO CLINIC via NATL INST OF HLTH NIA
Dec 2018 – Nov 2019
Identifying CxCR4 Receptor Agonists to Improve Diabetic Healing
Role: Project Manager
Funding: UNIV OF COLORADO DENVER & ANSCHUTZ MED via NATL INST OF HLTH NIDDK
Aug 2018 – Jul 2021
MRI: Acquisition of an X-Ray Diffractometer for Next Generation Functional Molecules and Materials
Role: Other
Funding: NATL SCIENCE FOU
Jul 2018 – Dec 2022
Alkaloid Ring Distortion: A Platform for New Cancer Therapies
Role: Co-Investigator
Funding: AMERICAN CANCER SOCIETY
Jul 2018 – Oct 2021
OR-DRPD-ROF2018: A C. elegans based drug discovery platform for modulators of re-mRNA processing
Role: Co-Investigator
Funding: UF RESEARCH
Sep 2017 – Aug 2020
Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma
Role: Co-Investigator
Funding: NATL INST OF HLTH NCATS
Dec 2016 ACTIVE
UF PASS: Regulation of exercise transducers
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Sep 2016 – Aug 2022
Development of Complex Natural Product Libraries and Multidimensional Anticancer Screening Platforms
Role: Other
Funding: NATL INST OF HLTH NCI
Jul 2016 – Jun 2018
NOVEL SYNTHETIC APRATOXINS ACTING THROUGH A NEW MECHANISM ASAN ALTERNATIVE TREATMENT OF CANCERS WITH ACTIVATED GROWTH…
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Jun 2014 – May 2017
Novel Therapeutics for activation of the antioxidant response
Role: Project Manager
Funding: UF DSR OPPORTUNITY FUND
Dec 2013 – Nov 2015
Chemistry and Biology of Apratoxins
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Mar 2013 – Aug 2019
Novel Targeted Anticancer Agents from Marine Cyanobacteria
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Mar 2011 – Feb 2016
Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for Atrophic Macular Degeneration
Role: Project Manager
Funding: NATL INST OF HLTH NEI

Education

Postdoctoral Fellow
2002-2005 · The Scripps Research Institute
Ph.D.
2002 · University of Hawaii at Manoa
Diplom in Chemistry
1997 · University of Siegen

Contact Details

Phones:
Business:
(352) 273-7738
Emails:
Business:
luesch@ufl.edu
Addresses:
Business Mailing:
PO Box 100485
GAINESVILLE FL 32610
Business Street:
MSB P3-12
1345 Center Drive
GAINESVILLE FL 326103003